I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase ..:
Vano, Yann-Alexandre
;
Elaidi, Réza
;
Bennamoun, Mostefa
...
info:eu-repo/semantics/altIdentifier/doi/10.1016/S1470-2045(22)00128-0. , 2022
Link:
https://hal.science/hal-04072026
RT Journal T1
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
UL https://suche.suub.uni-bremen.de/peid=base-ftunivcotedazur:oai:HAL:hal-04072026v1&Exemplar=1&LAN=DE A1 Vano, Yann-Alexandre A1 Elaidi, Réza A1 Bennamoun, Mostefa A1 Chevreau, Christine A1 Borchiellini, Delphine A1 Pannier, Diane A1 Maillet, Denis A1 Gross-Goupil, Marine A1 Tournigand, Christophe A1 Laguerre, Brigitte A1 Barthélémy, Philippe A1 Coquan, Elodie A1 Gravis, Gwenaelle A1 Houédé, Nadine A1 Cancel, Mathilde A1 Huillard, Olivier A1 Beuzeboc, Philippe A1 Fournier, Laure A1 Méjean, Arnaud A1 Cathelineau, Xavier A1 Doumerc, Nicolas A1 Paparel, Philippe A1 Bernhard, Jean-Christophe A1 de la Taille, Alexandre A1 Bensalah, Karim A1 Tricard, Thibault A1 Waeckel, Thibaut A1 Pignot, Géraldine A1 Braychenko, Elena A1 Caruso, Stefano A1 Sun, Cheng-Ming A1 Verkarre, Virginie A1 Lacroix, Guillaume A1 Moreira, Marco A1 Meylan, Maxime A1 Bougouïn, Antoine A1 Phan, Letuan A1 Thibault-Carpentier, Christelle A1 Zucman-Rossi, Jessica A1 Fridman, Wolf Herman A1 Sautès-Fridman, Catherine A1 Oudard, Stéphane PB HAL CCSD; Elsevier YR 2022 K1 MESH: Antineoplastic Combined Chemotherapy Protocols / adverse effects K1 MESH: Angiogenesis Inhibitors / adverse effects K1 MESH: Humans K1 MESH: Ipilimumab K1 MESH: Lipase K1 MESH: Male K1 MESH: Neoplasm Staging K1 MESH: Nivolumab / adverse effects K1 MESH: Prospective Studies K1 MESH: Protein Kinase Inhibitors / adverse effects K1 MESH: Sunitinib K1 MESH: Tumor Microenvironment K1 MESH: Biomarkers K1 MESH: Carcinoma K1 Renal Cell / drug therapy K1 MESH: Female K1 [SDV.CAN]Life Sciences [q-bio]/Cancer K1 [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy K1 [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology K1 [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie JF info:eu-repo/semantics/altIdentifier/doi/10.1016/S1470-2045(22)00128-0 LK http://dx.doi.org/https://hal.science/hal-04072026 DO https://hal.science/hal-04072026 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)